ReNeuron Group Stock

ReNeuron Group EBIT

Delisted

The EBIT of ReNeuron Group (RENE.L) as of Aug 13, 2026 is -7.12 M GBP. In the previous year, EBIT was -11.23 M GBP — a change of -36.60% (higher).

EBIT

-7.12 MGBP

YoY

-36.60%

Last updated:

In 2026, ReNeuron Group's EBIT was -7.12 M GBP, a -36.60% increase from the -11.23 M GBP EBIT recorded in the previous year.

The ReNeuron Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M GBP)
Date
EBIT (M GBP)
Jan 1, 2019
-18.30 base
Jan 1, 2020
-14.41 base
Jan 1, 2021
-12.99 base
Jan 1, 2022
-11.23 base
Jan 1, 2023
-7.12 base
Jan 1, 2024 (e)
-6.33 base
Jan 1, 2025 (e)
4.89 base
Jan 1, 2026 (e)
-11.67 base
YEAREBIT (M GBP)
2026 est -11.67
2025 est 4.89
2024 est -6.33
2023 -7.12
2022 -11.23
2021 -12.99
2020 -14.41
2019 -18.30
2018 -20.38
2017 -18.30
2016 -13.72
2015 -10.39
2014 -7.97
2013 -7.09
2012 -6.88
2011 -6.67
2010 -3.91
2009 -4.69
2008 -6.90
2007 -5.96
2006 -5.94
2005 -3.34
2004 -1.25
Access this data via the Eulerpool API

ReNeuron Group Revenue

ReNeuron Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
50,000.00 GBP
-18.30 M GBP
-14.35 M GBP
Jan 1, 2020
6.07 M GBP
-14.41 M GBP
-11.41 M GBP
Jan 1, 2021
260,000.00 GBP
-12.99 M GBP
-11.35 M GBP
Jan 1, 2022
400,000.00 GBP
-11.23 M GBP
-9.69 M GBP
Jan 1, 2023
530,000.00 GBP
-7.12 M GBP
-5.41 M GBP
Jan 1, 2024 (e)
660,540.00 GBP
-6.33 M GBP
103,862.34 GBP
Jan 1, 2025 (e)
12.23 M GBP
4.89 M GBP
103,862.34 GBP
Jan 1, 2026 (e)
1.19 M GBP
-11.67 M GBP
-11.23 M GBP

ReNeuron Group Margins

ReNeuron Group stock margins

The ReNeuron Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReNeuron Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReNeuron Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
100.00 %
-36,600.00 %
-28,700.00 %
Jan 1, 2020
100.00 %
-237.40 %
-187.97 %
Jan 1, 2021
100.00 %
-4,996.15 %
-4,365.39 %
Jan 1, 2022
100.00 %
-2,807.50 %
-2,422.50 %
Jan 1, 2023
100.00 %
-1,343.40 %
-1,020.75 %
Jan 1, 2024 (e)
100.00 %
-957.95 %
15.72 %
Jan 1, 2025 (e)
100.00 %
39.99 %
0.85 %
Jan 1, 2026 (e)
100.00 %
-978.84 %
-941.72 %

ReNeuron Group Stock analysis

What does ReNeuron Group do? The ReNeuron Group PLC is a British biopharmaceutical company specializing in the development of novel therapies for the treatment of neurological diseases such as stroke, Parkinson's, and spinal cord injuries. It was founded in 1997 and is headquartered in Guildford, Surrey. ReNeuron initially focused on researching stem cells, particularly neural stem cells, to use them for the regeneration of nerve tissue. This innovative method was intended to revolutionize the treatment of brain and spinal cord injuries. In 2006, the company successfully developed and conducted clinical trials on the first neural stem cell therapy candidate. However, the development of cellular therapies posed challenges, particularly in terms of product safety and efficacy. Therefore, ReNeuron adjusted its business strategy and has since been working on the development of exosomal products and bioproducts. Exosomes are small membrane vesicles secreted by cells. The proteins, nucleic acids, and lipids contained within them play a crucial role in cellular processes and could represent a new class of therapeutic agents. With these two new focuses, ReNeuron aims to continue being innovative and maintain its position as a leader in the biotech industry. The ReNeuron Group PLC is divided into three main areas: Core Business, NeuDiscovery, and Incubator. The Core Business is dedicated to the development and commercialization of novel therapeutic approaches for neurological diseases. The company works on the development of exosomal products, bioproducts, and cell-based therapies to aid in brain and spinal cord injuries. In developing these products, the company collaborates closely with leading research institutions, universities, and other biopharma companies. In NeuDiscovery, ReNeuron follows an "Open-Platform" strategy and provides external researchers with access to its exosomal drug library. The company expects this to lead to the discovery of new therapeutic approaches and the application of its own technology in other areas of medicine. Incubator is an internal initiative aimed at creating and supporting start-up biotech companies. The company offers its technology and expertise to this division and invests in promising projects. ReNeuron has also brought several significant products to the market in the past, including an experimental drug for the treatment of strokes based on neural stem cells. This therapeutic program has the potential to be a groundbreaking approach in stroke treatment, reducing the need for long-term medical interventions such as rehabilitation. Overall, ReNeuron is a strong force in the biotech industry and has the potential to revolutionize the face of medicine. The company has proven its ability to develop innovative and effective therapies while also adapting its business strategy to meet the regulations of the biopharmaceutical environment. ReNeuron Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ReNeuron Group's EBIT

ReNeuron Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ReNeuron Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ReNeuron Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ReNeuron Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ReNeuron Group stock

EBIT of ReNeuron Group is -7.12 M GBP in 2026.

EBIT of ReNeuron Group changed from -11.23 M GBP to -7.12 M GBP, representing a -36.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT ReNeuron Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's ReNeuron Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — ReNeuron Group

All Key Metrics — ReNeuron Group